REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February:
Guggenheim SMID Cap Biotech Conference
Presentation Date: Thursday, February 6, 2025 at 2:00 PM ET
Presentation Format: Fireside Chat
Webcast: https://wsw.com/webcast/guggen2/slno/2028708
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Presentation Date: Tuesday, February 11, 2025 at 2:40 PM ET
Presentation Format: Corporate Presentation
Webcast: https://wsw.com/webcast/oppenheimer39/slno/2814816
A replay of both events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
| Last Trade: | US$88.49 |
| Daily Change: | 3.23 3.79 |
| Daily Volume: | 1,476,309 |
| Market Cap: | US$4.460B |
July 01, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
